ArticleAmerican journal of preventive medicine2016
Trends in Use of Medications for Smoking Cessation in Medicare, 2007-2012.
Article in American journal of preventive medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- A randomized clinical trial testing two implementation strategies to promote the treatment of tobacco dependence in community mental healthcare.Drug and alcohol dependence · 2023Trial
- History and Correlates of Smoking Cessation Behaviors Among Smokers With Serious Mental Illness.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020Trial
- A Pilot Study to Evaluate the Use of Automated Nicotine Metabolite Ratio Reporting Within Primary Care as an Implementation Strategy to Increase the Use of Tobacco Treatments.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024Article
- Dental staff and patient attitudes about nicotine replacement therapy samples in dental care: A National Dental Practice-Based Research Network study.Community dentistry and oral epidemiology · 2024Article
- Access to effective smoking cessation medications in patients with medicare, medicaid and private insurance.Public health in practice (Oxford, England) · 2023Article
- Current Use of Cigarettes in the United States: The Joint Role of Race/Ethnicity and Health Insurance Coverage.Healthcare (Basel, Switzerland) · 2023Article
- Trends in Over-the-Counter Nicotine Replacement Therapy Sales, U.S., 2017‒2020.American journal of preventive medicine · 2023Article
- Smoking Cessation Medication Prescribing for Smokers With and Without Mental Illness.Psychiatric services (Washington, D.C.) · 2023Article
- Characterising the use of varenicline: an analysis of the Australian dispensing claims data.Addiction (Abingdon, England) · 2022Article
- Prescription Smoking-Cessation Medication Fills and Spending, 2009-2019.American journal of preventive medicine · 2022Article
- Article
- Symptoms of depression and active smoking among survivors of stroke and myocardial infarction: An NHANES analysis.Preventive medicine · 2020Article
- Trends in tobacco use and tobacco cessation counselling codes among Medicare beneficiaries, 2001-2014.BMC health services research · 2019Article
- National Trends in Cessation Counseling, Prescription Medication Use, and Associated Costs Among US Adult Cigarette Smokers.JAMA network open · 2019Article
- Changes in smoking cessation assistance in the European Union between 2012 and 2017: pharmacotherapy versus counselling versus e-cigarettes.Tobacco control · 2019Article
- Subsidized pharmacological treatment for smoking cessation by the Spanish public health system: A randomized, pragmatic, clinical trial by clusters.Tobacco induced diseases · 2019Article
- National Trends in Smoking Cessation Medication Prescriptions for Smokers With Chronic Obstructive Pulmonary Disease in the United States, 2007-2012.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2018Observational
- Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States.Drug and alcohol dependence · 2017Observational
- Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy.Journal of the American Pharmacists Association : JAPhAArticle
- Simulating the Fiscal Impact of Anti-Obesity Medications as an Obesity Reduction Strategy.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionSmoking-related disease accounts for 10% of Medicare expenditures. Although clinical guidelines recommend smoking-cessation medications, they are subject to safety warnings from the U.S. Food and Drug Administration (FDA). This study investigated trends in utilization of smoking-cessation medications in Medicare from 2007 to 2012.
methodsData on medical claims and prescription drugs for a nationally representative sample of Medicare beneficiaries were used to study trends from 2007 to 2012 in use of smoking-cessation medications (bupropion, nicotine-replacement therapy, varenicline), among beneficiaries who used tobacco (N=205,675). Analyses were conducted in 2015. Multinomial logistic regression was used to examine differences in use of bupropion, nicotine-replacement therapy, varenicline, or more than one medication, relative to none, by beneficiaries' health and demographic characteristics. Binary logistic regression calculated average predicted probabilities of cardiovascular disease or depression among medication users before and after FDA safety warnings related to those conditions.
resultsSixteen percent of tobacco users ever filled a prescription for a smoking-cessation medication. The proportion of beneficiaries who filled prescriptions for varenicline increased in 2007 but sharply declined corresponding to public warnings about adverse effects, although the same trends did not occur for bupropion or nicotine-replacement therapy. After FDA safety concerns were published, the average predicted probability of beneficiaries filling varenicline prescriptions with cardiovascular disease declined by 31%, although the average predicted probability of depression did not decline.
conclusionsUse of smoking-cessation medications among Medicare beneficiaries remains low. Health effects of Medicare policies that increase coverage for medical support for smoking cessation may be limited by low utilization of effective medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.